Collect Product
Product Details
Synonyms
AITR, GITR, TNFRSF18, CD357
Source
Canine GITR, His Tag (GIR-C52H6) is expressed from human 293 cells (HEK293). It contains AA Gly 23 - Pro 154 (Accession # D7F619-1).
Predicted N-terminus: Gly 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.8 kDa. The protein migrates as 20-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Canine GITR, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA
Immobilized Canine GITR, His Tag (Cat. No. GIR-C52H6) at 2 μg/mL (100 μL/well) can bind Human GITR Ligand, Fc Tag (Cat. No. GIL-H526a) with a linear range of 2-40 ng/mL (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Glucocorticoid-induced tumor necrosis factor receptor-related protein
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
4 Details
- Highest R&D Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
